Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
R. Struniawski, A. Szpechcinski, J. Zaleska, M. Chabowski, T. Orlowski, K. Roszkowski, E. Rogala, J. Chorostowska-Wynimko (Warsaw, Poland). The predictive value of total vs. amplificable free-circulating DNA in plasma of NSCLC patients – a preliminary study. Eur Respir J 2008; 32: Suppl. 52, 3550

Member's Comments

No comment yet.

Related content which might interest you: The clinical significance of plasma DNA quantification in NSCLC Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 PTGER4, a promising novel DNA methylation marker for lung cancer measured in a clinical case control study using blood plasma Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 The detection of quantitative serum p53 protein in lung cancer and its clinical value Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients. Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Circulating free DNA concentration is an independent prognostic biomarker in lung cancer Source: Eur Respir J 2015; 46: 1773-1780 Year: 2015 Immunological factors in NSCLC patients with possible predictive and prognostic value under PDL-1 treatment-a pilot study Source: International Congress 2019 – Treatment of lung cancer Year: 2019 LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Real-time PCR analysis of free-circulating DNA in plasma of non-small cell lung cancer patients Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009 Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Loss of heterozygosity detected in plasma DNA of early stage lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004